Evidence map›Paper›PMID 40503370›Full record

ArticleWorld journal of stem cells2025

Human umbilical cord mesenchymal stem cells ameliorate liver metabolism in diabetic rats with metabolic-associated fatty liver disease.

Ke-Bing Zhou, Li Nie, Mei-Li Wang, Dong-Hua Xiao, Hai-Yan Zhang, Xia Yang, Duan-Fang Liao, Xue-Feng Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ke-Bing ZhouDepartment of Gastroenterology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan Province, China.
Li NieDepartment of Gastroenterology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan Province, China.
Mei-Li WangDepartment of Gastroenterology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan Province, China.
Dong-Hua XiaoDepartment of Gastroenterology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan Province, China.
Hai-Yan ZhangDepartment of General Practice, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan Province, China.
Xia YangDepartment of General Practice, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan Province, China.
Duan-Fang LiaoDepartment of Gastroenterology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan Province, China.
Xue-Feng YangDepartment of Gastroenterology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes mellitus (DM) and metabolic-associated fatty liver disease (MAFLD) are common metabolic disorders, and their coexistence can exacerbate the progression of either disease. Human umbilical cord mesenchymal stem cell (hUC-MSC) therapy has shown promising potential in the treatment of several metabolic diseases.

aimTo investigate how hUC-MSCs affect liver metabolism in diabetic rats with MAFLD and assess their therapeutic potential and underlying mechanisms.

methodsA streptozotocin-induced rat model of DM with MAFLD was established, and hUC-MSCs were administered

resultshUC-MSC treatment significantly reduced FBG and TG levels in diabetic rats with MAFLD and improved histological steatosis and injury in the liver. Metabolomic analysis indicated that hUC-MSCs significantly ameliorated liver metabolic disturbances

conclusionhUC-MSCs alleviate liver metabolic disturbances in diabetic rats with MAFLD, thereby mitigating the pathological state of DM and slowing the progression of MAFLD.

Indexed as

Blood glucoseDiabetes mellitusHuman umbilical cord mesenchymal stem cellsLiver functionLiver metabolismMetabolic-associated fatty liver diseaseTriglyceride

Identifiers

PMID40503370
PMCPMC12149798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.